Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OVID vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)
OVID Overall Winner
6-Pillar Tally: OVID 3 – 2 EVMN (1 Tie)
Matrix Metrics: OVID 7 – 2 EVMN
As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OVID carries a Unified Composite Score of 43.5/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. EVMN 30.0/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OVID vs EVMN
OVID
Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
$2.40
-5.51% 1D
Market Cap
$479.4M
TTM Revenue
$1.5M
Forward P/E
1.8x
Beta / 30D Vol
0.98β · 97% Vol
Unified Composite Score
43.5
HOLD
Tech 15.0
Fund 42.0
Flow 67.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
EVMN
Evommune, Inc.
$7.10
-6.95% 1D
Market Cap
$315.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.05β · 118% Vol
Unified Composite Score
30.0
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (OVID 3 – 2 EVMN)
1. Valuation Multiples
OVID
Forward P/E
1.8x
N/M
Trailing P/E
1.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
OVID
Revenue Growth (YoY)
-88.3%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.5M
N/A
Market Cap
$479.4M
$315.5M
3. Profitability & Quality
OVID
Gross Margin
100.0%
N/A
Operating Margin
-4693.7%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-35.4%
-69.5%
4. Balance Sheet & Cash Flow
EVMN
Cash Generation (TTM)
-$58M
-$75M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.5M Net Cash
$52M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EVMN
Options Structure Phase
CONSOLIDATION
SURGE
Current IV / %ile
131.0% (30th %ile)
209.0% (53rd %ile)
Put/Call OI Skew
0.07x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OVID (7) vs EVMN (2)| Institutional Metric | OVID | EVMN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $479.4M | $315.5M | OVID | |
| Trailing P/E Ratio | 1.8x | N/M | OVID | |
| Forward P/E Ratio | 1.8x | N/M | OVID | |
| Revenue Growth (YoY) | -88.3% | +0.0% | EVMN | |
| Operating Margin (TTM) | -4693.7% | 0.0% | EVMN | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -35.4% | -69.5% | OVID | |
| 52-Week Range Position | 63% ($1–$3) | 8% ($5–$33) | OVID | |
| Beta / 30D Volatility | 0.98β · 97% Vol | 1.05β · 118% Vol | OVID | |
| Unified Institutional Score | 43.5 / 100 (HOLD) | 30.0 / 100 (SELL) | OVID | |
| Trailing 12M Revenue (USD) | $1.5M | N/A | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$58M ($1.5M Net Cash) | -$75M ($52M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EVMN +25.7 pp
3M Horizon
OVID +34.58 pp
6M Horizon
OVID +67.16 pp
1Y Horizon
OVID +161.03 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OVID Revenue | EVMN Revenue | OVID Op. Margin | EVMN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $10M | N/A | -645.4% | N/A | OVID |
| FY2021 | $210M | N/A | 59.6% | N/A | OVID |
| FY2022 | $0M | N/A | -3696.4% | N/A | OVID |
| FY2023 | $0M | N/A | -15122.7% | N/A | OVID |
| FY2024 | $0M | $10M | -10933.7% | -1000.2% | EVMN |
| FY2025 | $10M | $10M | -585.2% | -623.6% | OVID |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OVID
CONSOLIDATION
Current IV
131.0%
IV Percentile
30th %ile
Put/Call OI Skew
0.07x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EVMN
SURGE
Current IV
209.0%
IV Percentile
53rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OVID Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EVMN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OVID vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OVID carries a Unified Composite Score of 43.5/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. EVMN 30.0/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
OVID leads the Growth & Scale pillar: OVID posts -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), OVID cumulative revenue shifted +0.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, OVID deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
OVID screens cheaper on headline valuation multiples. OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OVID (-35.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 97% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EVMN vs OVID · Reverse Pair
OVID vs CRVS
· Sector Peer
OVID vs ASMB
· Sector Peer
OVID vs KALA
· Sector Peer
EVMN vs MPLT
· Sector Peer
EVMN vs ALMS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem